Clinical details for BU patients enrolled in the study.

<p>*STR = WHO recommended treatment of 8 weeks streptomycin and rifampicin;</p>#<p>‘Category’ refers to WHO clinical severity scoring system for BU E = edematous, N = nodule, Q = Plaque, U = ulcerative.</p

Details for household contacts enrolled in the study.

<p>Details for household contacts enrolled in the study.</p

Clinical presentation of three, confirmed BU patients enrolled in this study showing: (A) nodule of the right knee; (B) ulcer of the right elbow; (C) ulcer of the left hand at diagnosis; and (D) ulcer of the right elbow 6 weeks post diagnosis and commence

<p>Clinical presentation of three, confirmed BU patients enrolled in this study showing: (A) nodule of the right knee; (B) ulcer of the right elbow; (C) ulcer of the left hand at diagnosis; and (D) ulcer of the right elbow 6 weeks post diagnosis and commencement of SR8 with surgical intervention.</p

Chest radiographs of patient before and during antibiotic chemotherapy for <i>M. ulcerans</i> disease.

<p>(A) Chest X-ray taken before antibiotic therapy was started. (B) Chest X-ray taken 2 weeks after initiation of antibiotic therapy, showing bilateral pleural effusions. (C) Week 3 after drainage of pleural effusion. (D) Recurrence of pleural effusion on the right hemithorax at week 4.</p

An extensive category III oedematous lesion involving the anterior and posterior chest and neck regions, with two ulcers: one at the anterior triangle of the neck, measuring 6 cm x 8 cm, and another over the midsternal region of the chest, measuring 3 cm x 4 cm.

<p>An extensive category III oedematous lesion involving the anterior and posterior chest and neck regions, with two ulcers: one at the anterior triangle of the neck, measuring 6 cm x 8 cm, and another over the midsternal region of the chest, measuring 3 cm x 4 cm.</p

NEFA assay (Cohort 3).

<p>NEFA assay (Cohort 3).</p

NEFA assay (Cohort 3).

<p>NEFA assay (Cohort 3).</p

Abnormal metabolic responses to <i>M. ulcerans</i> infection.

<p>Effect of BUD on the serum level of various indicators of liver and renal function is shown. Data are presented as Box and Whiskers in Ctrl and BUD patients. *p<0.01, **p<0.005, ***p<0.001, NS: not significant.</p

FACS analysis (Part of Cohort 2).

<p>FACS analysis (Part of Cohort 2).</p

Suppression of multiple serum proteins in patients with BUD.

<p>A) O-PLS-DA of serum protein levels in healthy donors (Ctrl) versus BUD patients at week 0 (BUD 0, left) or week 12 (BUD 12, right). Score plots displaying predictive t[1] versus orthogonal t_O[1] components are shown, with 95% confidence ellipses (based on Hotelling's T2 statistic) showing the absence of outliers. B) SUS-plot resulting from these O-PLS-DA models. Variables situated along the indicated diagonal are comparably modulated in BUD 0 and BUD 12, compared to Ctrl. The more reliable (pcorr[1] close to −1 and +1) are labelled.</p